Ca 2+-activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction

British Journal of Pharmacology

Volumn 169, Issue 2, 2013, Pages 449-461

  Gonzalez Corrochano R ^a,b   La Fuente, J M ^c   Cuevas, P ^a   Fernandez A ^a   Chen, M X ^d   Angulo, J ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

calcium activated potassium channels; diabetes; erectile dysfunction; human corpus cavernosum; human penile resistance arteries; NS 8; NS1619; PDE5; sildenafil

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; BENZIMIDAZOLE DERIVATIVE; CARBOLINE DERIVATIVE; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; VASODILATOR AGENT;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFICACY; ELECTROSTIMULATION; ENDOTHELIUM; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PENIS ARTERY; PRIORITY JOURNAL; VASODILATATION; ANIMAL; DOSE RESPONSE; DRUG EFFECT; ELECTROSTIMULATION THERAPY; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PENIS; RAT; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ADULT; AGED; ANIMALS; BENZIMIDAZOLES; CARBOLINES; CYCLIC GMP; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION THERAPY; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PENIS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; PURINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; VASODILATION; VASODILATOR AGENTS;

EID: 84876947729     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12143     Document Type: Article

References (68)

1. Angulo J, Rodriguez-Mañas L, Peirõ C, Neira M, Marín J, Sánchez-Ferrer CF, (1998). Impairment of nitric oxide mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 358: 529-537.
2. Angulo J, Cuevas P, La Fuente JM, Pomerol JM, Ruiz-Castañé E, Puigvert A, et al. (2002). Regulation of human penile smooth muscle tone by prostanoid receptors. Br J Pharmacol 136: 23-30.
3. Angulo J, Cuevas P, Fernandez A, Gabancho S, Videla S, Sáenz de Tejada I, (2003). Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile resistance arteries. Br J Pharmacol 139: 854-862.
4. Angulo J, Cuevas P, Gabancho S, Gonzalez-Corrochano R, Videla S, Saenz de Tejada I, (2005). Enhancement of both, endothelium-derived hyperpolarizing factor and nitric oxide/cyclic guanosin-monophosphate pathways reverses erectile dysfunction in diabetic rats. J Sex Med 2: 317-322.
5. Angulo J, González-Corrochano R, Cuevas P, Fernández A, La Fuente JM, Rolo F, et al. (2010a). Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J Sex Med 7: 758-768.
6. Angulo J, Wright HM, Cuevas P, González-Corrochano R, Fernández A, Cuevas B, et al. (2010b). Nebivolol dilates penile arteries and reverses erectile dysfunction in diabetic rats through enhancement of nitric oxide signaling. J Sex Med 7: 2681-2697.
7. Angulo J, Cuevas P, Fernández A, La Fuente JM, Allona A, Moncada I, et al. (2012). Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med 9: 2293-2306.
8. Bivalacqua TJ, Usta MF, Champion HC, Leungwattanakij S, Dabisch PA, McNamara DB, et al. (2004). Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res 16: 21-29.
9. Boulton AJ, Selam JL, Sweeney M, Ziegler D, (2001). Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 44: 1296-1301.
10. + channel in human endothelium. Cardiovasc Res 60: 488-496.
11. 2+) channel of intermediate conductance in bovine aortic endothelial cells. J Membr Biol 163: 147-158.
12. + channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum. Naunyn Schmiedebergs Arch Pharmacol 369: 602-615.
13. Christ GJ, Spray DC, Brink PR, (1993). Characterization of K currents in cultured human corporal smooth muscle cells. J Androl 14: 319-328.
14. Christ GJ, Day N, Santizo C, Sato Y, Zhao W, Sclafani T, et al. (2004). Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol 287: H1544-H1553.
15. Climent B, Schubert R, Stankevicius E, García-Sacristán A, Simonsen U, Rivera L, (2012). Large conductance Ca2+-activated K+ channels modulate endothelial cell outward currents and nitric oxide release in the intact rat superior mesenteric artery. Biochem Biophys Res Commun 417: 1007-1013.
16. El-Sakka AI, (2004). Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol 46: 503-509.
17. Fedele D, Bortolotti A, Coscelli C, Santeusanio F, Chatenoud L, Colli E, et al. (2000). Erectile dysfunction in type 1 and type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int J Epidemiol 29: 524-531.
18. Ca channel gene. J Physiol 545: 829-836.
19. Ghatta S, Nimmagadda D, Xu X, O'Rourke ST, (2006). Large-conductance, calcium-activated potassium channels: structural and functional implications. Pharmacol Ther 110: 103-116.
20. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA, (1998). Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338: 1397-1404.
21. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T, (2003). Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 26: 777-783.
22. Ca channels. FASEB J 18: 1382-1391.
23. Gratzke C, Angulo J, Chitaley K, Dai Y-T, Kim NN, Paick J-S, et al. (2010). Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 7: 445-475.
24. + channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 25: 704-709.
25. Hedlund H, Andersson KE, (1985). Comparison of the responses to drugs acting on adrenoreceptors and muscarinic receptors in human isolated corpus cavernosum and cavernous artery. J Auton Pharmacol 5: 81-88.
26. Hewawasam P, Fan W, Cook DA, Newberry KS, Boissard CG, Gribkoff VK, et al. (2004). 4-Aryl-3-(mercapto)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle. Bioorg Med Chem Lett 14: 4479-4482.
27. Ca channel activator, NS1619, on rat cerebral artery smooth muscle. Br J Pharmacol 117: 119-129.
28. Kalsi JS, Kell PD, Cellek S, Ralph DJ, (2004). NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. Int J Impot Res 16: 195-200.
29. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
30. + channels in human mesenteric artery. A single-cell reverse transcriptase- polymerase chain reaction and electrophysiological study in situ. Circ Res 87: 496-503.
31. + channels in the endothelial cell layer involved in modulation of neurogenic contractions in rat penile arteries. Eur J Pharmacol 474: 103-115.
32. + channels, enhances erectile responses in rats. Br J Pharmacol 158: 1465-1476.
33. 2+-activated potassium channels in smooth muscle cells of the human corpus cavernosum. Urol Res 29: 359-365.
34. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
35. + channel openers in bladder and vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 369: 481-489.
36. ATP channel openers: structure-activity relationships and therapeutic potential. Med Res Rev 24: 213-266.
37. Melman A, Zhao W, Davies KP, Bakal R, Christ GJ, (2003). The succesful long-term treatment of age related erectile dysfunction with hSlo cDNA in rats in vivo. J Urol 170: 285-290.
38. Morgado M, Cairrao E, Santos-Silva AJ, Verde I, (2012). Cyclc nucleotide-dependent relaxation pathways in vascular smooth muscle. Cell Mol Life Sci 69: 247-266.
39. Mulvany MJ, Halpern W, (1977). Contractile properties of small resistance arteries in spontaneously hypertensive and normotensive rats. Circ Res 41: 19-26.
40. Nardi A, Olesen SP, (2008). BK channel modulators: a comprehensive overview. Curr Med Chem 15: 1126-1146.
41. + channels by novel benzimidazolone. Eur J Pharmacol 251: 53-59.
42. Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, et al. (2001). On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13: 2-9.
43. + channel modulators on human prostate cancer cell proliferation. Eur J Pharmacol 471: 157-164.
44. + channels: ion flux studies by atomic absorption spectrometry. Assay Drug Dev Technol 1: 647-654.
45. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, et al. (2001). The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 13: 192-199.
46. + (KCa) channels are involved in the relaxation elicited by sildenafil in penile resistance arteries. Eur J Pharmacol 531: 232-237.
47. Rendell MS, Rajfer J, Wicker PA, Smith MD, for the Sildenafil Diabetes Study Group (1999). Sildenafil for treatment of erectile dysfunction in men with diabetes. A randomized controlled trial. JAMA 281: 421-426.
48. + channels in relaxation of penile resistance arteries. Urology 63: 800-805.
49. Sáenz de Tejada I, Anglin G, Knight JR, Emmick JT, (2002). Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 25: 2159-2164.
50. Sánchez A, Villalba N, Martínez AC, García- Sacristán A, Hernández M, Prieto D, (2008). Mechanisms of the relaxant effect of vardenafil in rat penile arteries. Eur J Pharmacol 586: 283-287.
51. Sausbier M, Schubert R, Voigt V, Hirneiss C, Pfeifer A, Korth M, et al. (2000). Mechanisms of NO/cGMP-dependent vasorelaxation. Circ Res 87: 825-830.
52. Schubert R, Nelson MT, (2001). Protein kinases: tuners of the BKCa channel in smooth muscle. Trends Pharmacol Sci 22: 505-512.
53. Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M, (2000). Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 52: 557-594.
54. +-channels. Br J Pharmacol 116: 2582-2590.
55. + channel activation with NS1619 decreases myogenic and neurogenic contraction of rat detrusor smooth muscle. Eur J Pharmacol 670: 252-259.
56. Spektor M, Rodríguez R, Rosenbaum RS, Wang H-Z, Melman A, Christ GJ, (2002). Potassium channels and human corporeal smooth muscle cell tone: further evidence of the physiological relevance of the maxi-K channel subtype to the regulation of human corporeal smooth muscle tone in vitro. J Urol 167: 2628-2635.
57. Stuckey BG, Jadzinsky MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F, et al. (2003). Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 26: 279-284.
58. Taher A, Meyer M, Stief CG, Jonas U, Forssmann WG, (1997). Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol 15: 32-35.
59. Tanaka Y, Koike K, Toro L, (2004). MaxiK channel roles in blood vessel relaxations induced by endothelium-derived relaxing factors and their molecular mechanisms. J Smooth Muscle Res 40: 125-153.
60. Venkateswarlu K, Giraldi A, Zhao W, Wang H-Z, Melman A, Spektor M, et al. (2002). Potassium channels and human corporeal smooth muscle cell tone: diabetes and relaxation of human corpus cavernosum smooth muscle by adenosine triphosphate sensitive potassium channel openers. J Urol 168: 355-361.
61. Vickers MA, Satyanarayana R, (2002). Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 14: 466-471.
62. + channels in vascular endothelial cells. J Biol Chem 280: 11656-11664.
63. Werner ME, Zvara P, Meredith AL, Aldrich RW, Nelson MT, (2005). Erectile dysfunction in mice lacking the large-conductance calcium-activated potassium (BK) channel. J Physiol 567: 545-566.
64. Werner ME, Meredith AL, Aldrich RW, Nelson MT, (2008). Hypercontractility and impaired sildenafil relaxations in the BKCa channel deletion model of erectile dysfunction. Am J Physiol Regul Integr Comp Physiol 295: R181-R188.
65. + channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A 97: 8151-8156.
66. Zhang XH, Filippi S, Morelli A, Vignozzi L, Luconi M, Donati S, et al. (2006). Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 3: 253-264.
67. Ca channel by cGMP and cAMP kinase. J Biol Chem 276: 43239-43245.
68. Ziegler D, Merfort F, van, Ahlen H, Yassin A, Reblin T, Neureither M, (2006). Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 3: 883-891.